AI assistant
Transcode Therapeutics, Inc. — Director's Dealing 2021
Jul 9, 2021
35264_dirs_2021-07-08_5c8c34db-dfb4-4942-8d1f-834cbe333b48.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Transcode Therapeutics, Inc. (RNAZ)
CIK: 0001829635
Period of Report: 2021-07-08
Reporting Person: Moore Anna (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1552785 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.091 | 2025-07-01 | Common Stock (60655) | Direct |
Footnotes
F1: Twenty-five percent (25%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (January 1, 2020), provided that the Optionee continues to have a Service Relationship with the Company at such time. Thereafter, the remaining seventy-five percent (75%) of the Stock Options shall vest and become exercisable in 36 equal monthly installments on the last day of each month beginning with the month of the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship with the Company on each vesting date.